Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

BioCis Pharma Starts A Phase I Clinical Trial With A New Cancer Drug
BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.
generic viagra online
Rabies: How To Protect Yourself And Your Pets
Rabies is a virus that occurs in mammals and infects the central nervous system; the disease can cause death in humans if it is not treated. Nearly 90 percent of cases occur in wild animals (raccoons, bats, foxes etc.); less than 10% of cases occur in domestic animals like dogs or cats. Humans usually become infected when they are bitten by an infected animal.
News of the day
Abraxis Bioscience Completes Enrollment Of Pivotal Phase III Advanced Lung Cancer Study Evaluating Abraxane(R) Vs. Taxol(R)
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced that the company has completed patient enrollment of a pivotal, phase III clinical study comparing the company"s chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) with Taxol® (paclitaxel) injection, both in combination with carboplatin, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The study, which is being conducted at 111 sites globally, includes 1,050 patients and is being led by principal investigator Dr. Mark Socinski at the University of North Carolina Lineberger Comprehensive Cancer Center. It is one of the largest NSCLC clinical studies to complete enrollment.
Endocrinology

Mediterranean Diet Decreases Dementia

Research released at the International Conference on Alzheimer"s Disease suggests that adhering to a Mediterranean diet may decrease risk of dementia. It is also linked to benefits for people with high blood pressure or pre-hypertension. The study used a survey which included a cognitive assessment and food frequency questions in order to observe developments across an 11 year period. The results suggested a diet which included vegetables, grains, low-fat dairy and nuts may aid cognitive function. "The study adds weight to a growing body of evidence which suggests that a Mediterranean diet full of green leafy vegetables, oily fish and the odd glass of red wine is the best type of diet for those who want to follow a diet that can help lower their chances of developing dementia. Some studies have shown this can type of diet can reduce your risk by up to 40%." Professor Clive Ballard Director of Research Alzheimer"s Society Reference: Wengreen, RD, PHD. Dietary Approaches to Stop Hypertension (DASH) diet adherance scores and cognitive decline and dementia among aging men and women: Cashe County study of Memory Health and Ageing. Notes - International Conference of Alzheimer"s Disease runs from 11 - 16 July 2009 for further information please visit ICAD. - One in three people over 65 will die with dementia - Alzheimer"s Society research shows that 700,000 people in the UK have a form of dementia, more than half have Alzheimer"s disease. In less than 20 years nearly a million people will be living with dementia. This will soar to 1.7 million people by 2051. - Alzheimer"s Society champions the rights of people living with dementia and the millions of people who care for them. - Alzheimer"s Society works in England, Wales and Northern Ireland - Alzheimer"s Society needs to raise money to help people live well with dementia today and for research to find a cure for tomorrow. You can donate now by calling 0845 306 0898 or visiting http://www.alzheimers.org.uk Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009